In contrast to the WT1 TED that showed reduced cytotoxicity, WT1 TED2 split demonstrated significantly augmented cytotoxicity against two WT1-HLA-A*02:01+ tumor cell lines (Figure 2A; Supplementary Figure 7, Supplementary Table 2). The gene discussed is HLA-A; the disease is neoplasm.